ILUMYA
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Pressure score
50
Momentum score
43
Why This Matters
Roche is a direct competitive threat because it is already approved in Immunology · IL-23 (ILUMYA) and could narrow Merck's development lead.
Competitive Assessment
- Threat type
- direct competitor
- Development stage
- Approved
- Stage gap
- Competitor is at a comparable development stage, indicating head-to-head race dynamics.
- Market share risk
- Share risk is emerging — primarily strategic positioning rather than immediate revenue displacement.
Strategic Action
Align with signal posture: monitor. Monitor direct competitor activity and refresh competitive intelligence after material readouts.
Overlap Analysis
Source Analysis
FDA accepts supplemental Biologics License Application for Roche’s Lunsumio and Polivy combination for people with relapsed or refractory large B-cell lymphoma
Roche's ILUMYA directly references the same indication focus (Immunology · IL-23) as this signal.
Source: Humanexa Signals
No public source document URL on file.
Related Signal
FDA Accepts Supplement for ILUMYA (Tildrakizumab) by Sun Pharma
Open signalCompetitor Position
Not enough competitive findings for a race view.